U.S. federal trademark · Serial No. 74287806 · Reg. No. 1754392
evaluating, adapting and implementing advanced cancer treatment programs at out-patient centers under the direction of practicing oncologists, the primary treatments involving high-dose chemotherapy coupled with support of the patient's immune system through the use of autologous peripheral blood stem cell reinfusion, and related pharmacy and out-patient infusional services
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.